Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma

Journal of Urology

Volumn 193, Issue 1, 2015, Pages 41-47

  Santoni, Matteo ^a   Conti, Alessandro ^a   Porta, Camillo ^b   Procopio, Giuseppe ^c   Sternberg, Cora N ^d   Basso, Umberto ^g   De Giorgi, Ugo ^h   Bracarda, Sergio ⁱ   Rizzo, Mimma ^j   Ortega, Cinzia ^l   Massari, Francesco ^m   Iacovelli, Roberto ^c   Derosa, Lisa ⁿ   Masini, Cristina ^o   Milella, Michele ^e   Di Lorenzo, Giuseppe ^k   Atzori, Francesco ^p   Pagano, Maria ^q   Buti, Sebastiano ^r   De Vivo, Rocco ^s   Mosca, Alessandra ^t   Rossi, Marta ^u   Paglino, Chiara ^b   Verzoni, Elena ^c   Cerbone, Linda ^d   Muzzonigro, Giovanni ^a   Falconi, Massimo ^a   Montironi, Rodolfo ^a   Burattini, Luciano ^a   Santini, Daniele ^f   Cascinu, Stefano ^a   more..

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^g VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^h DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

ⁱ IRCCS POLICLINICO SAN DONATO   (Italy)

^j CARDARELLI HOSPITAL   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^l CANDIOLO CANCER INSTITUTE   (Italy)

^m UNIVERSITY OF VERONA   (Italy)

ⁿ UNIVERSITY HOSPITAL OF PISA   (Italy)

^o UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^p DEPARTMENT OF RADIOLOGY   (Italy)

^q S MARIA NUOVA HOSPITAL   (Italy)

^r UNIVERSITY HOSPITAL OF PARMA   (Italy)

^s SAN BORTOLO HOSPITAL   (Italy)

^t MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^u SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

more..

Author keywords

carcinoma; protein tyrosine kinases; recurrence; renal cell; survival

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ADRENAL METASTASIS; ADULT; AGE; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL OUTCOME; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; KIDNEY METASTASIS; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDIASTINUM METASTASIS; MSKCC SCORE; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PANCREAS METASTASIS; PLEURA METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADICAL NEPHRECTOMY; RETROPERITONEAL CANCER; RETROSPECTIVE STUDY; SCORING SYSTEM; SOFT TISSUE METASTASIS; SPLEEN METASTASIS; STOMACH CANCER; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; FEMALE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; SECONDARY;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SULFONAMIDES;

EID: 85033725666     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.07.011     Document Type: Article

References (28)

1. Escudier, B., Advanced renal cell carcinoma: current and emerging management strategies. Drugs, 67, 2007, 1257.
2. Singer, E.A., Gupta, G.N., Marchalik, D., et al. Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol, 25, 2013, 273.
3. Mekhail, T.M., Abou-Jawde, R.M., Boumerhi, G., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol, 23, 2005, 832.
4. Sandock, D.S., Seftel, A.D., Resnick, M.I., A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol, 154, 1995, 28.
5. Lam, J.S., Shvarts, O., Leppert, J.T., et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol, 174, 2005, 466.
6. Zisman, A., Pantuck, A.J., Dorey, F., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol, 19, 2001, 1649.
7. McNichols, D.W., Segura, J., DeWeerd, J.H., Renal cell carcinoma: long-term survival and late recurrence. J Urol, 126, 1981, 17.
8. Nakano, E., Fujioka, H., Matsuda, M., et al. Late recurrence of renal cell carcinoma after nephrectomy. Eur Urol, 10, 1984, 347.
9. Miyao, N., Naito, S., Ozono, S., et al. Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer. Urology, 77, 2011, 379.
10. Escudier, B., Pluzanska, A., Koralewski, P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet, 370, 2007, 2103.
11. Rini, B.I., Halabi, S., Rosenberg, J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol, 26, 2008, 5422.
12. Escudier, B., Eisen, T., Stadler, W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356, 2007, 125.
13. Motzer, R.J., Hutson, T.E., Tomczak, P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 2007, 115.
14. Sternberg, C.N., Davis, I.D., Mardiak, J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 28, 2010, 1061.
15. Rini, B.I., Escudier, B., Tomczack, P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet, 378, 2011, 1931.
16. Hudes, G., Carducci, M., Tomczak, P., et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med, 356, 2007, 2271.
17. Motzer, R.J., Escudier, B., Oudard, S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind randomised placebo-controlled phase III trial. Lancet, 372, 2008, 449.
18. Iacovelli, R., Alesini, D., Palazzo, A., et al. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treat Rev, 40, 2014, 271.
19. Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 2009, 228.
20. Fagerland, M.W., Hosmer, D., Bofin, A.M., Multinomial goodness-of-fit tests for logistic regression models. Stat Med, 27, 2008, 4238.
21. Mickey, R.M., Greenland, S., The impact of confounder selection criteria on effect estimation. Am J Epidemiol, 129, 1989, 125.
22. Brookman-May, S., May, M., Shariat, S.F., et al. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol, 64, 2013, 472.
23. Bianchi, M., Sun, M., Jeldres, C., et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol, 23, 2012, 973.
24. Kume, H., Kakutani, S., Yamada, Y., et al. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors?. J Urol, 185, 2011, 1611.
25. McKay, R.R., Kroeger, N., Xie, W., et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol, 65, 2014, 577.
26. Grassi, P., Verzoni, E., Mariani, L., et al. Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. Clin Genitourin Cancer, 4, 2013, 484.
27. Kroeger, N., Choueiri, T.K., Lee, J.L., et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol, 65, 2014, 1086.
28. Motzer, R.J., Hutson, T.E., Cella, D., et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med, 369, 2013, 22.